Recent studies have implicated local inflammation and complement activation in the pathogenesis of age-related macular degeneration (AMD) and geographic atrophy. It has been suggested that amyloid beta is linked to these local inflammatory processes, identifying it as a potential interventional target to reduce inflammatory response and limit the progression of geographic lesions. This video briefly details data presented at this year’s ARVO congress, in Seattle, US (Wednesday 04 May 2016, 09:00-09:15 PM, Session 403). Authors Lashkari et al. from the Schepens Eye Institute, USA concluded that the amyloid beta plasma levels were significantly higher in patients with geographic atrophy, supporting the hypothesis that targeting amyloid beta may help reduce the progression of geographic atrophy.
Systemic levels of amyloid β
Other Perspective
Managing GA in clinical practice: new challenges, new models
With the new treatments for GA, it is important to re-think the management of patients looking at th
The new era in the management of patients with geographic atrophy
Paolo Lanzetta discusses with Baruch Kuppermann about the new treatments for geographic atrophy appr
Euretina 2023 – Controversies and future trends in intravitreal therapies
IVEG instructional course – Euretina 2023Take-home messagesIn this video, the best of our
Home monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r
Related Articles
